Explore our materials

Filters

Results (5255)

Slideset

HIV

European HIV Clinical Forum 2016

A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti

Daniel Kuritzkes

Slideset

HIV

European HIV Clinical Forum 2016

Impact on: Virology/Resistance - Daniel Kuritzkes, MD

Slideset

HIV

European HIV Clinical Forum 2016

Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP

Slideset

HIV

International Workshop on HIV Transmission 2016

Research update: drug development - Myron Cohen, MD

Slideset

HIV

International Workshop on HIV Transmission 2016

The Role of TAF in PrEP - Katy Garrett, PharmD

Slideset

HIV

International Workshop on HIV Transmission 2016

Studies in early acute infection and implications for transmission and cure - Merlin Robb, MD

Slideset

HIV

International Workshop on HIV Transmission 2016

The fine specificity and autologous virus neutralization potency of maternal antibodies that predict reduced HIV-1 mother to child transmission - Sallie Permar, MD, PhD

Slideset

HIV

International Workshop on HIV Transmission 2016

Study of early development of broadly neutralizing antibodies in HIV-1-infected infants - Cassandra Simonich, MD/PhD Candidate

Slideset

HIV

HIV DART and Emerging Viruses 2016

Collateral Damage with Antiviral Therapy | David Thomas, MD, MPH

Scott Letendre

Slideset

HIV

HIV DART and Emerging Viruses 2016

Management of Neurocognitive Impairment of Aging Populations Living with HIV | Scott Letendre, MD

Slideset

HIV

HIV DART and Emerging Viruses 2016

(Abstract) Antiviral Activity of tenofovir alafenamide against HIV-1 with thymidine analog mutation(s) and M184V | C. Callebaut

Slideset

HIV

HIV DART and Emerging Viruses 2016

(Abstract) Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF) | B. Baugh

Explore our materials

Your Selection Clear All

Topic

Material Type

A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti

Impact on: Virology/Resistance - Daniel Kuritzkes, MD

Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP

Research update: drug development - Myron Cohen, MD

The Role of TAF in PrEP - Katy Garrett, PharmD

Studies in early acute infection and implications for transmission and cure - Merlin Robb, MD

The fine specificity and autologous virus neutralization potency of maternal antibodies that predict reduced HIV-1 mother to child transmission - Sallie Permar, MD, PhD

Study of early development of broadly neutralizing antibodies in HIV-1-infected infants - Cassandra Simonich, MD/PhD Candidate

Collateral Damage with Antiviral Therapy | David Thomas, MD, MPH

Management of Neurocognitive Impairment of Aging Populations Living with HIV | Scott Letendre, MD

(Abstract) Antiviral Activity of tenofovir alafenamide against HIV-1 with thymidine analog mutation(s) and M184V | C. Callebaut

(Abstract) Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF) | B. Baugh